Oguro M, Takagi T
Gan To Kagaku Ryoho. 1982 Mar;9(3):508-15.
Twenty-two patients with malignant lymphoma and its allied diseases, consisting of 6 with Hodgkin's disease, 10 with non-Hodgkin's's diffuse lymphoma, 4 with leukemic lymphosarcoma and 2 with immunoblastic lymphadenopathy, were entered into this study. The treatment schedule was intravenous drip infusion of the drug, at a dose of 2.3 to 5.4 mg/kg (150 mg to 300 mg/day), for consecutive 4 to 14 days. The total dose given ranged from 1050 to 2500 mg. Four of the 6 patients with Hodgkin's disease and 5 of the 10 patients with non-Hodgkin's diffuse lymphoma showed a good response. The response started from 3 to 7 days after beginning of BH-AC administration and remission induced by BH-AC persisted for 4 weeks. Clinical toxicities such as anorexia, nausea and vomiting were very mild, but hematological toxicities such as thrombocytopenia, leukopenia, and anemia were frequent especially in the patients who were totally given more than 2100 mg. This study suggested that malignant lymphoma responded definitely to single administration of BH-AC and that BH-AC might be a new useful drug for multi-combined chemotherapy of malignant lymphoma.
本研究纳入了22例恶性淋巴瘤及其相关疾病患者，其中包括6例霍奇金病患者、10例非霍奇金弥漫性淋巴瘤患者、4例白血病性淋巴肉瘤患者和2例免疫母细胞性淋巴结病患者。治疗方案为静脉滴注该药物，剂量为2.3至5.4毫克/千克（150毫克至300毫克/天），连续4至14天。总给药剂量为1050至2500毫克。6例霍奇金病患者中有4例、10例非霍奇金弥漫性淋巴瘤患者中有5例显示出良好反应。反应在开始使用BH-AC后3至7天出现，BH-AC诱导的缓解持续4周。厌食、恶心和呕吐等临床毒性非常轻微，但血小板减少、白细胞减少和贫血等血液学毒性较为常见，尤其是在总给药量超过2100毫克的患者中。本研究表明，恶性淋巴瘤对单次使用BH-AC有明确反应，且BH-AC可能是恶性淋巴瘤多药联合化疗的一种新的有用药物。
